

IMTEC-GASTRO-LIA

Gastro-LIA

Line Immuno Assay (LIA) for the Detection of Antibodies in Gastrointestinal Diseases (IgA and IgG)

(d-Gliadin, tTG, Mannan, PCA, IF)

Package Size

REF	ITC30701	24 Tests	Complete Testkit
IVD			

Please read the instructions carefully before testing

Intended Use

IMTEC-Gastro-LIA is an indirect membrane based enzyme immunoassay for the qualitative determination of IgA and IgG class antibodies against deamidated gliadin (d-gliadin, DGP), tissue transglutaminase (tTG), mannan (ASCA), parietal cell antigen (PCA) and intrinsic factor (IF) in human serum or plasma. The assay is intended for in vitro diagnostic use only as an aid in the diagnosis of celiac disease, pernicious anemia and inflammatory bowel diseases.

Celiac disease and dermatitis herpetiformis (Dühring's disease), which often occur in association with a gluten sensitive enteropathy are serologically characterised by the occurrence of IgA antibodies against endomysial connective tissue. This type of enteropathy is called celiac disease and typically manifests within the first few years of life, but sometimes also in adulthood. Gluten incompatibility leads to chronic digestive insufficiency, which is accompanied by damage to the intestinal mucosa and other symptomatic changes and troubles.

Tissue transglutaminase (tTG) has been identified as antigen to the anti-endomysial antibodies (EMA). The wheat protein gliadin, a component of gluten, has been described among others as substrate of tTG. About 10 % of patients with celiac disease have an IgA deficiency; therefore, the serum should also be tested with the IgG conjugate if this deficiency is suspected.

The antibody titre strictly correlates with disease activity but decreases once a gluten free diet has been initiated. One to 12 months later, usually no antibodies against tTG can be detected.

A characteristic feature of the disease, apart from the occurrence of tTG-antibodies, is the occurrence of anti-d-gliadin IgG and/or IgA antibodies. In case of celiac disease, these antibodies occur isolated or in conjunction with tTG-antibodies and are therefore important for diagnosis and assessment of its course. The presence of anti-d-gliadin antibodies IgA is celiac disease-specific, whereas antibodies of the IgG type may also occur in other diseases (Crohn's disease: 40–50%, ulcerative colitis: 10–20%).

Anti-Saccharomyces cerevisiae antibodies (ASCA, antigen: mannophosphopeptide, mannan) are autoantibodies that occur in Crohn's disease, a chronic inflammatory bowel disorder.

ASCA have a high specificity (97%) and positive predictive value (96%) for Crohn's disease, especially when assessed in combination with a negative pANCA test result.

Antibodies to parietal cell antigens (PCA) were first described in patients with a pernicious anaemia (Addison's anaemia) and occur in patients with autoimmune endocrinal thyroid diseases like Hashimoto's Thyroiditis and diabetes mellitus type I (20–30%) as well as chronic atrophic gastritis type A, too.

Anti-IF antibodies are mainly found in patients with pernicious anemia (Addison's anemia, vitamin B12 deficiency anemia). Individuals over 60 years of age are affected most often. These antibodies are also detected in patients with chronic atrophic gastritis type A (risk for development of pernicious anemia) and autoimmune thyroid diseases.

Principle

The test is based on the principle of the line immuno assay (LIA). The antigens are applied as lines on a nitrocellulose membrane:

antigens	identity
d-Gliadin	recombinant
tTG	recombinant
ASCA	native
PCA	recombinant
IF	recombinant

The nitrocellulose membrane is blocked to prevent unspecific reactions. During incubation of a strip with diluted patient samples autoantibodies present in the sample will bind to the antigen(s) on the strip. For the detection of the bound antibodies a secondary horseradish peroxidase (HRP)-labelled anti-human IgG/IgA antibody is used. After addition of the

substrate and stop solution, the appearance of brown lines indicates the existence of (auto) antibodies against the respective antigen.

Kit Content

STRIP	24	Test Strips (black colour coding) coated with antigen (see table), ready for use
DIL LIA	3 Bottles	Powder for the preparation of 30 ml dilution buffer (blue cap)
WASH 20x WB03	50 ml	Washing Buffer (black cap) concentrate (20x) for 1 l buffer
CON A	29 ml	Conjugate Solution (green cap) anti-human-IgA HRP conjugate, ready for use
CON G	29 ml	Conjugate Solution (white cap) anti-human-IgG HRP conjugate, ready for use
SUB LIA	30 ml	Substrate Solution (black cap) ready for use colourless to bluish 3,3', 5,5'-tetramethylbenzidin hydrogen peroxide
STOP LIA	26 ml	Stop Solution (red cap) sulphuric acid, ready for use
	2 pcs.	Incubation Tray
	1 pc.	Scoring sheet, Tweezers, Bonding Sheet,
	each	transparent Evaluation Template

Safety Notes

Do not swallow the reagents. Avoid contact with eyes, skin and mucous membranes. All patient specimens should be handled as potentially infectious. Wear protective clothing and disposable gloves according to Good Laboratory Practices.

All materials contaminated with patient specimens should be inactivated by validated procedures (autoclaving or chemical treatment) in accordance with applicable regulations.

STOP LIA, **SUB LIA** can irritate eyes, skin and mucous membranes. Upon contact, rinse thoroughly with copious amounts of water and consult a doctor.

Stability

When stored at 2...8°C unopened vials are stable until the expiry date.

After reconstitution, **DIL LIA** and **WASH** and opened **CON** are stable for 6 weeks at 2...8°C.

Store **SUB LIA** protected from light.

Precautions

DIL LIA, **WASH|20x|WB03** and **SUB LIA** may be interchanged between lots and LIA test kits that share the same reagent designation.

All other reagents are specific for the individual test kit lot and must not be interchanged with other lots and test kits.

Do not use polystyrene vessels for handling of **CON**.

Any crystallised salt of **WASH|20x|WB03** inside the bottle must be resolved before use.

Do not dry **STRIP** during the incubation steps.

Do not touch **STRIP** with fingers, use tweezers.

Remove diluted samples completely after incubation of **STRIP** to avoid cross contamination.

Use rocking shaker during all incubation steps.

Specimen, Controls

Serum and plasma with the anticoagulants citrate or EDTA.

Do not use highly lipemic, hemolysed or icteric specimens.

Undiluted specimens may be stored for 5 days at 2...8°C, or for one year at -20°C. **Freeze and thaw once only.** Thawed specimen should be carefully homogenised. Eliminate particulate matter by centrifugation or filtration.

Reagent preparation

Bring all reagents to **room temperature** (15...25°C) before use.

Reagents not in use should always be stored at 2...8°C.

Washing Buffer Solution **WASH**

Dilute 1 part **WASH|20x|WB03** with 19 parts distilled water.

Dilution buffer Solution **DIL LIA**

Dissolve the content of one bottle **DIL LIA** with 30 ml of **WASH** and agitate well.

Procedure

Wash Procedure

The wash procedure is critical. Insufficient washing will result in poor precision or falsely high band intensity.

W1: Remove liquids completely.

W2: Add [WASH] and incubate for 5 min with gentle agitation.

W3: After washing, remove remaining liquid.

Pipetting Scheme

Follow the procedure exactly as described. Pay particular attention to the washing procedure!

Reagents and specimens should be at room temperature before use.

Sample Preparation:

Dilute specimen 1:101 with reconstituted [DIL|LIA]

1 ml is needed for each well.

Step 1	Well [ml]
Insert [STRIP] into the incubation tray colour coding facing up	--
[WASH] to wet the membrane	1
Incubate 1 min. at room temperature	
Remove [WASH]	
Step 2	
Diluted samples	1
Incubate 30 min. at room temperature	
Wash 3 times as described (see W1 - W3)	
[WASH]	1
Step 3	
[CON A] or [CON G]	1
Incubate 30 min. at room temperature	
Wash 3 times as described (see W1 - W3)	
[WASH]	1
Step 4	
[SUB LIA]	1
Incubate 10 min. at room temperature	
Remove [SUB LIA]	
Step 5	
Add distilled water	1
Incubate 1 min. at room temperature	
Remove distilled water	
[STOP LIA]	1
Incubate 5 min. at room temperature	
Remove [STOP LIA]	
Dry [STRIP] thoroughly	

Automation

The IMTEC-Gastro-LIA may be processed with suitable automated Blot analyzers. Applications have to be validated in prior to diagnostic use. For automated interpretation of the results we recommend using HumaScan.

Test Validation

The test results are valid provided the following criteria are met for each [STRIP]:

- Function control is visible.
- Cut-off control is visible.
- Intensity function control > intensity cut-off control

Interpretation of Results

Fix [STRIP] onto scoring sheet and align the reference line of the [STRIP] with the reference line on the scoring sheet.

Align the dotted reference line of the evaluation template with the reference line of the [STRIP].

The interpretation of the test results takes place exclusively on basis of the respective cut-off control regarded for each [STRIP]:

The test result is **negative**, if no band is to be recognised or if the band exhibits a smaller intensity in comparison to the cut-off control.

The test is **equivocal**, if the intensity of the band and the intensity of the cut-off control do not significantly differ.

The test result is **positive**, if a band exhibits a stronger staining in comparison to the cut-off control.

Record the respective test results on the scoring sheet.

Limitations

A positive result must be used in association with clinical evaluation and diagnostic procedures. The values obtained from this assay are intended to be an aid for diagnosis only.

The intensity of the band colour does not necessarily correlate with antibody titres as obtained with other reference methodologies. Samples from apparent normal blood donors may contain autoantibodies.

If the patient sample contains elevated levels of immune complexes or other immunoglobulin aggregates, false positive results by non-specific binding cannot be ruled out.

Performance Characteristics

Typical performance data can be found in the Verification Report, accessible via:

www.human.de/data/gb/vr/la-30701.pdf or

www.human-de.com/data/gb/vr/la-30701.pdf

Note

The handling should always be in compliance with common GLP requirements (*)! The validation criteria must be met!

(*This includes: Proper caps being replaced on the vials and firmly tightened / Remove only reagents required for a run from stock solutions if they could come into contact with other contaminating solutions like patient specimens etc. / Stock solutions always returned to 2...8°C when not in use.)

Colour coding

The colour coding attached above the reference serves the identification of the available IMTEC-LIA-tests:

colour coding	IMTEC-LIA test
yellow	ANA-LIA
orange	ANA-LIA-Maxx
blue	Myositis-LIA
brown	Liver-LIA S
purple	Vasculitis-LIA
black	Gastro-LIA

References

1. Conrad K. *et al.*, Autoantibodies in Systemic Autoimmune Diseases – A Diagnostic Reference; Pabst Science Publishers, Lengerich, Berlin, Riga, Rom, Viernheim, Wien, Zagreb, 2008
2. Olen O. *et al.*, Antibodies against deaminated gliadin peptides and tissue transglutaminase for diagnosis of pediatric celiac disease, *JPGN* **55:6**, 695-700, 2012
3. Schwartz E. *et al.*, Serologic assay based on gliadin related nonapeptides as a highly sensitive and specific diagnostic aid in celiac disease, *Clinical Chemistry* **50:12**, 2370-2375, 2004

LA-30701

INF ITC30701 GB

01-2014-15M

